Skip to content

Tag: Cholinergic agonist

Explore our medication guides and pharmacology articles within this category.

What is Salagen used for?

4 min read
Salagen, a cholinergic agonist, was approved by the FDA in 1994 for treating dry mouth. It is primarily a prescription medication, and understanding what is Salagen used for is crucial for those suffering from severe xerostomia caused by specific medical conditions.

What is the use of carbachol? A Comprehensive Guide to its Clinical Applications

3 min read
Carbachol is a potent cholinergic agonist that mimics the effects of acetylcholine, primarily used in the eye for therapeutic purposes. This versatile drug plays a critical role in ophthalmology, where its actions help manage intraocular pressure and control pupil size during surgical procedures. Exploring what is the use of carbachol reveals its distinct advantages over other miotic agents due to its long-lasting effects.

Which Adverse Effect Is Most Likely to Occur with Administration of Bethanechol?

3 min read
An estimated 0.8% of 17.3 million clinic visits by women for urinary tract symptoms resulted in a bethanechol prescription [1.3.5]. But which adverse effect is most likely to occur with administration of bethanechol? The most common side effects are related to its cholinergic activity, including urinary urgency, stomach cramps, and sweating [1.2.1].

Which are common side effects of bethanechol?

5 min read
Approximately 0.8% of clinic visits by women for urinary tract symptoms between 2003 and 2013 resulted in a bethanechol prescription, indicating its niche use. Understanding which are common side effects of bethanechol is crucial for managing treatment effectively and knowing when to contact a healthcare provider.

Is there a generic version of Tyrvaya?

4 min read
Approximately 16 million people in the U.S. have been diagnosed with dry eye disease [1.8.4]. For those seeking affordable treatment, a common question is: **Is there a generic version of Tyrvaya?** As of September 2025, the answer is no [1.2.2].